Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice

• Published in: Molecular genetics and metabolism reports 2019-12, Vol.21, p.100510, Article 100510
• Main Authors: Gustavsson, Susanne, Ohlin Sjöström, Elisabet, Tjernberg, Agneta, Janson, Juliette, Westermark, Ulrica, Andersson, Tommy, Makower, Åsa, Arnelöf, Erik, Andersson, Gudrun, Svartengren, Jan, Ekholm, Carina, Svensson Gelius, Stefan
• Format: Article
• Language: English
• Subjects: Enzyme replacement therapy; Heparan sulfate; Mucopolysaccharidosis IIIA; Neuroinflammation; Research Paper; Sanfilippo; Sulfamidase
• ISSN: 2214-4269; 2214-4269
• DOI: 10.1016/j.ymgmr.2019.100510

Mucopolysaccharidosis type IIIA (MPS IIIA) is a lysosomal storage disorder (LSD) characterized by severe central nervous system (CNS) degeneration. The disease is caused by mutations in the SGSH gene coding for the lysosomal enzyme sulfamidase. Sulfamidase deficiency leads to accumulation of heparan sulfate (HS), which triggers aberrant cellular function, inflammation and eventually cell death. There is currently no available treatment against MPS IIIA. In the present study, a chemically modified recombinant human sulfamidase (CM-rhSulfamidase) with disrupted glycans showed reduced glycan receptor mediated endocytosis, indicating a non-receptor mediated uptake in MPS IIIA patient fibroblasts. Intracellular enzymatic activity and stability was not affected by chemical modification. After intravenous (i.v.) administration in mice, CM-rhSulfamidase showed a prolonged exposure in plasma and distributed to the brain, present both in vascular profiles and in brain parenchyma. Repeated weekly i.v. administration resulted in a dose- and time-dependent reduction of HS in CNS compartments in a mouse model of MPS IIIA. The reduction in HS was paralleled by improvements in lysosomal pathology and neuroinflammation. Behavioral deficits in the MPS IIIA mouse model were apparent in the domains of exploratory behavior, neuromuscular function, social- and learning abilities. CM-rhSulfamidase treatment improved activity in the open field test, endurance in the wire hanging test, sociability in the three-chamber test, whereas other test parameters trended towards improvements. The unique properties of CM-rhSulfamidase described here strongly support the normalization of clinical symptoms, and this candidate drug is therefore currently undergoing clinical studies evaluating safety and efficacy in patients with MPS IIIA.